NewAmsterdam Pharma Company NAMS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's total current liabilities?
- NewAmsterdam Pharma Company (NAMS) reported total current liabilities of $67.42M in Q1 2026.
- How has NewAmsterdam Pharma Company's total current liabilities changed year-over-year?
- NewAmsterdam Pharma Company's total current liabilities increased by 64.8% year-over-year, from $40.91M to $67.42M.
- What is the long-term trend for NewAmsterdam Pharma Company's total current liabilities?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total current liabilities has grown at a 33.5% compound annual growth rate (CAGR), from $36.06M to $85.79M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.